Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.
Malapelle U, Pilotto S, Passiglia F, Pepe F, Pisapia P, Righi L, Listì A, Bironzo P, Belluomini L, Tabbò F, Reale ML, Russo G, De Luca C, Novello S, Troncone G. Malapelle U, et al. Among authors: passiglia f. Crit Rev Oncol Hematol. 2021 Apr;160:103300. doi: 10.1016/j.critrevonc.2021.103300. Epub 2021 Mar 17. Crit Rev Oncol Hematol. 2021. PMID: 33744362 Review.
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, Castiglia M, Rizzo S, Vullo FL, Fiorentino E, Van Meerbeeck J, Russo A. Bronte G, et al. Among authors: passiglia f. Crit Rev Oncol Hematol. 2014 Feb;89(2):300-13. doi: 10.1016/j.critrevonc.2013.08.003. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041630
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Rolfo C, et al. Among authors: passiglia f. Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Cancer Treat Rev. 2014. PMID: 24953979 Free article. Review.
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D, Bronte G, Passiglia F, Calò V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listì A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, Bazan V. Fanale D, et al. Among authors: passiglia f. Anal Cell Pathol (Amst). 2015;2015:690916. doi: 10.1155/2015/690916. Epub 2015 Sep 21. Anal Cell Pathol (Amst). 2015. PMID: 26484003 Free PMC article. Review.
Nintedanib in NSCLC: evidence to date and place in therapy.
Bronte G, Passiglia F, Galvano A, Barraco N, Listì A, Castiglia M, Rizzo S, Fiorentino E, Bazan V, Russo A. Bronte G, et al. Among authors: passiglia f. Ther Adv Med Oncol. 2016 May;8(3):188-97. doi: 10.1177/1758834016630976. Epub 2016 Feb 16. Ther Adv Med Oncol. 2016. PMID: 27239237 Free PMC article. Review.
115 results